Adding carbamazepine to olanzapine.
- Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
- Carbamazepine is principally metabolized by CYP3A4, and is a potent inducer of CYP1A2, CYP2C9, CYP3A4 and UDP-glucuronosyltransferases.
- This combination of drugs may have possible synergistic effects. However, the pharmacokinetic drug interactions will influence the plasma levels. Dose adaptation will be recommended for this combination.
- Consider alternative for carbamazepine, otherwise start carbamazepine according to the general dosing advice.
- Check clinical effect or olanzapine plasma concentration after 2 weeks and adapt dose if necessary.  
- Close clinical monitoring for evidence of altered olanzapine effect is recommended in patients receiving carbamazepine.
- KNMP; Informatorium Medicamentorum 2015; Monografie "olanzapine" (Dutch)
Cite error: Invalid
<ref>tag; name "informatorium" defined multiple times with different content
- Farmacotherapeutisch Kompas; Toxicologie (dutch) Cite error: Invalid
<ref>tag; name "ftktox" defined multiple times with different content
- Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics; J Clin Psychiatry 2003;64:663-667
- WHO Collaborating Centre for Drug Statistics Methodology ATC=N03AF01
- Farmacotherapeutisch Kompas - carbamazepine (dutch)
- Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002.
- Bazire S, Psychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.